Share
 
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
16:30
WEAB0301
Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study
Norbert Bräu, Mount Sinai School of Medicine, United States
Abstract
Slides

16:45
WEAB0302
Drug-drug interactions studies between HCV antivirals sofosbuvir and velpatasvir and HIV antiretrovirals
Annie Luetkemeyer, University of California, United States
Abstract
PDF

17:00
WEAB0303
Higher mortality in HIV-HBV co-infected persons with elevated HBV replication in the Temprano Trial
Menan Gérard Kouamé, National Agency for AIDS Research (ANRS), Cote D'Ivoire
Abstract
Slides

17:15
WEAB0304LB
TURQUOISE-I Part 2: safety and efficacy of ombitasvir + paritaprevir/r ± dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection
Jürgen K. Rockstroh, University of Bonn, Germany
Abstract
Slides

17:30
WEAB0305LB
Hepatitis B viral load response to two antiviral regimens (tenofovir/lamivudine vs lamivudine) in HIV and HBV co-infected pregnant women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study
Liming Wang, China
Abstract

17:45
WEAB0306
Moderated discussion